enGene Therapeutics ENGN Cash Flow Statement (2022-2026)

NASDAQ ENGN
$1.58 -0.05 (-3.07%)
At close: Oct 22, 2026 · 4:00 PM EDT
Reported Financials

enGene Therapeutics Quarterly Cash Flow Statement

Periods 16 quarters
Latest Jul 2026

enGene Therapeutics reported cash from operations of -$18.95M and free cash flow of -$18.95M for the quarter ended Jul 2026, up 26.1% year over year. This cash flow statement covers 16 quarters of results from Oct 2022 through Jul 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Oct2022 Jan2023 Apr2023 Jul2023 Oct2023 Jan2024 Apr2024 Jul2024 Oct2024 Jan2025 Apr2025 Jul2025 Oct2025 Jan2026 Apr2026 Jul2026
Operating Activities
Net Income -7.42M-5.28M-4.72M-82.50M-10.71M-14.98M-14.15M-15.30M-24.62M-25.82M-28.99M-37.88M-29.75M-30.23M-32.50M
Depreciation and DepletionDep. & Depletion 0.05M0.04M0.04M0.05M0.08M0.08M0.08M0.08M0.10M0.11M0.13M0.17M0.19M0.18M0.18M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Dep. & Amort. 0.05M0.04M0.04M0.07M0.08M0.10M0.10M0.10M0.10M0.10M0.10M0.20M0.19M0.20M0.10M
Share-based CompensationStock Comp. 0.02M0.04M0.04M3.35M0.29M1.92M1.46M1.66M1.81M2.65M2.58M2.61M2.80M4.15M7.81M
Other non-cash itemsOther Non-Cash 2.26M0.34M-2.58M44.43M0.57M0.11M0.17M0.16M0.29M0.05M0.20M-0.07M0.49M-0.14M-0.04M
Change in Working Capital
Change in Account PayablesChange Payables 0.83M1.22M-1.08M-0.60M0.22M-0.91M2.61M-1.45M1.13M-0.97M0.82M3.97M-4.27M-0.63M0.74M
Change in Accured ExpensesChange Accured Exp. -1.82M-0.45M0.17M2.97M2.15M0.41M3.20M-0.54M-3.88M3.92M-1.06M4.15M4.39M-2.49M5.04M
Change in Other Operating AssetsOther Assets Change 0.06M0.13M0.61M-0.05M1.27M0.79M1.59M3.92M-0.42M1.77M-1.36M-1.99M2.42M1.58M-0.10M
Change in Other Operating LiabilitiesOther Liabilities Change 0.04M0.00M-0.04M-0.04M-0.17M0.08M0.13M0.23M0.04M-0.28M-0.29M
Other Working Capital ChangesOther WC Changes -0.06M-0.13M-0.61M0.05M-1.23M-0.79M-1.64M-3.96M0.25M-1.69M1.49M2.22M-2.38M-1.86M-0.20M
Cash from OperationsCash from Ops. -6.22M-4.44M-7.30M-6.78M-7.37M-14.16M-7.18M-19.57M-25.70M-22.95M-25.63M-24.96M-28.90M-30.50M-18.95M
Investing Activities
Capital ExpendituresCapex 0.01M0.01M0.16M0.14M0.51M0.18M0.00M0.24M0.30M0.05M0.70M0.44M0.15M0.10M
Change in Property, Plant and EquipmentChange in PP&E -0.01M-0.01M-0.16M-0.14M-0.51M-0.18M0.00M-0.24M-0.30M-0.05M-0.70M-0.44M-0.15M-0.10M
Purchase of InvestmentsInvestments Purchased 94.67M13.76M44.67M7.75M169.19M50.21M42.38M
Sale and Maturity of InvestmentsInvestments Sold 10.00M31.75M46.76M48.69M43.04M73.95M72.50M
Cash from Investing ActivitiesCash from Investing -0.01M-0.01M-0.16M-0.14M-0.51M-0.18M0.00M-125.27M-84.96M17.95M1.38M40.50M-126.30M23.64M30.12M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance 30.00M22.50M25.00M
Non-Current Debt 30.00M22.50M25.00M
Net Debt Issuances and RepaymentsNet Debt Issuance 30.00M22.50M25.00M
Change in Capital Stock
Common Stock IssuedStock Issued 56.92M0.05M60.16M0.00M0.20M0.03M1.99M149.78M0.00M0.02M
Net Shares Issued and RepurchasedNet Shares Issued 56.92M0.05M60.16M0.00M0.20M0.03M1.99M149.78M0.00M0.02M
Net Equity Issued and RepurchasedNet Equity Issued 56.92M0.05M60.16M0.00M0.20M0.03M1.99M149.78M0.00M0.02M
Other financing activitiesOther financing -0.44M-0.14M-10.06M0.07M
Cash from Financing ActivitiesCash from Financing -0.01M7.76M27.55M50.84M12.00M193.51M0.05M60.16M0.00M0.20M-0.67M1.99M141.66M0.07M0.02M
Additional items
Exchange Rate EffectFX Effect 0.00M0.00M0.00M0.00M
Change in Cash -6.25M3.31M20.10M43.93M4.13M179.16M-7.13M-84.67M-110.66M-4.80M-24.92M17.53M-13.54M-6.79M11.20M
Ending Cash Balance 20.43M14.19M17.50M37.59M81.52M85.65M264.81M257.68M173.00M62.35M57.55M32.62M50.15M36.61M29.83M41.03M
Free Cash FlowFCF -6.24M-4.45M-7.46M-6.91M-7.88M-14.34M-7.18M-19.81M-26.00M-22.99M-26.34M-25.40M-29.06M-30.60M-18.95M
Net Cash FlowNCF -6.25M3.31M20.10M43.93M4.12M179.16M-7.13M-84.67M-110.66M-4.80M-24.92M17.53M-13.54M-6.79M11.20M
Interest Paid 0.27M0.46M0.28M0.58M0.53M0.53M0.53M0.51M0.53M0.71M0.54M0.46M0.59M

enGene Therapeutics Cash Flow Statement API

Pull enGene Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=ENGN&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY